Virilization Panel 1
Ordering Recommendation

Aids in the detection and subclassification of hyperandrogenism. Most useful in women and children with moderate/severe hirsutism or hirsutism of any degree when it is sudden in onset or rapidly progressive. Hirsutism Evaluation Panel is generally preferred.

Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
1-4 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Serum separator tube or green (sodium or lithium heparin). Collect between 6-10 a.m. Also acceptable: Lavender (EDTA). 
Specimen Preparation
Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min 0.5 mL) 
Storage/Transport Temperature
Unacceptable Conditions
Ambient: 2 hours; Refrigerated: 1 week; Frozen: 6 months 
Reference Interval
Test Number
Reference Interval
2001638AndrostenedioneEffective August 19, 2013
Premature Infants, 26-28 weeks-Day 40.92-2.82 ng/mL0.92-2.82 ng/mL
Premature Infants, 31-35 weeks-Day 40.80-4.46 ng/mL0.80-4.46 ng/mL
Full-term Infants, 1-7 days0.20-2.90 ng/mL0.20-2.90 ng/mL
8-30 days0.18-0.80 ng/mL0.18-0.80 ng/mL
1-5 months0.06-0.68 ng/mL0.06-0.68 ng/mL
6-24 monthsLess than 0.15 ng/mL0.03-0.15 ng/mL
2-3 yearsLess than 0.16 ng/mLLess than 0.11 ng/mL
4-5 years0.02-0.21 ng/mL0.02-0.17 ng/mL
6-7 years0.02-0.28 ng/mL0.01-0.29 ng/mL
8-9 years0.04-0.42 ng/mL0.03-0.30 ng/mL
10-11 years0.09-1.23 ng/mL0.07-0.39 ng/mL
12-13 years0.24-1.73 ng/mL0.10-0.64 ng/mL
14-15 years0.39-2.00 ng/mL0.18-0.94 ng/mL
16-17 years0.35-2.12 ng/mL0.30-1.13 ng/mL
18-39 years0.26-2.14 ng/mL0.33-1.34 ng/mL
40 years and older0.13-0.82 ng/mL0.23-0.89 ng/mL
Pre-menopausal0.26-2.14 ng/mLDoes Not Apply
Postmenopausal0.13-0.82 ng/mLDoes Not Apply
Tanner Stage I0.05-0.51 ng/mL0.04-0.32 ng/mL
Tanner Stage II0.15-1.37 ng/mL0.08-0.48 ng/mL
Tanner Stage III0.37-2.24 ng/mL0.14-0.87 ng/mL
Tanner Stage IV-V0.35-2.05 ng/mL0.27-1.07 ng/mL

2001640Dehydroepiandrosterone, Serum or PlasmaEffective August 19, 2013
PrematureLess than 40 ng/mLLess than 40 ng/mL
0-1 dayLess than 11 ng/mLLess than 11 ng/mL
2-6 daysLess than 8.7 ng/mLLess than 8.7 ng/mL
7 days-1 monthLess than 5.8 ng/mLLess than 5.8 ng/mL
1-5 monthsLess than 2.9 ng/mLLess than 2.9 ng/mL
6-24 monthsLess than 1.9 9 ng/mLLess than 2.5 ng/mL
2-3 yearsLess than 0.85 ng/mLLess than 0.63 ng/mL
4-5 yearsLess than 1.03 ng/mLLess than 0.95 ng/mL
6-7 yearsLess than 1.79 ng/mL0.06-1.93 ng/mL
8-9 years0.14-2.35 ng/mL0.10-2.08 ng/mL
10-11 years0.43-3.78 ng/mL0.32-3.08 ng/mL
12-13 years0.89-6.21 ng/mL0.57-4.10 ng/mL
14-15 years1.22-7.01 ng/mL0.93-6.04 ng/mL
16-17 years1.42-9.00 ng/mL1.17-6.52 ng/mL
18-39 years1.33-7.78 ng/mL1.33-7.78 ng/mL
40 years and older0.63-4.70 ng/mL0.63-4.70 ng/mL
Postmenopausal0.60-5.73 ng/mLDoes Not Apply
Tanner Stage I0.14-2.76 ng/mL0.11-2.37 ng/mL
Tanner Stage II0.83-4.87 ng/mL0.37-3.66 ng/mL
Tanner Stage III1.08-7.56 ng/mL0.75-5.24 ng/mL
Tanner Stage IV-V1.24-7.88 ng/mL1.22-6.73 ng/mL

0081058Testosterone, Females or ChildrenEffective August 19, 2013
Premature (26-28 weeks)5-16 ng/dL59-125 ng/dL
Premature (31-35 weeks)5-22 ng/dL37-198 ng/dL
Newborn20-64 ng/dL75-400 ng/dL
1-5 monthsLess than 20 ng/dL14-363 ng/dL
6-24 monthsLess than 9 ng/dLLess than 37 ng/dL
2-3 yearsLess than 20 ng/dLLess than 15 ng/dL
4-5 yearsLess than 30 ng/dLLess than 19 ng/dL
6-7 yearsLess than 7 ng/dLLess than 13 ng/dL
8-9 years1-11ng/dL2-8 ng/dL
10-11 years3-32 ng/dL2-165 ng/dL
12-13 years6-50 ng/dL3-619 ng/dL
14-15 years6-52 ng/dL31-733 ng/dL
16-17 years9-58 ng/dL158-826 ng/dL
18-39 years9-55 ng/dL300-1080 ng/dL
40-59 years9-55 ng/dL300-890 ng/dL
60 years and older5-32 ng/dL300-720 ng/dL
Premenopausal (18 years and older)9-55 ng/dLDoes Not Apply
Postmenopausal5-32 ng/dLDoes Not Apply
Tanner Stage I2-17 ng/dL2-15 ng/dL
Tanner Stage II5-40 ng/dL3-303 ng/dL
Tanner Stage III10-63 ng/dL10-851 ng/dL
Tanner Stage IV-V11-62 ng/dL162-847 ng/dL

Interpretive Data
Total testosterone values may not reflect optimal concentrations in all individuals. Free or bioavailable testosterone measurements may provide supportive information.

Statement B: Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Hotline History
CPT Code(s)
Component Test Code*Component Chart NameLOINC
0081058Testosterone, LC-MS/MS2986-8
2001639Androstenedione by TMS1854-9
2001641Dehydroepiandrosterone by TMS2193-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please view this test within the Laboratory Test Directory found at
  • Androstenedione (Virilization Panel 1)
  • Dehydroepiandrosterone (Virilization Panel 1)
  • Testosterone (Virilization Panel 1)